Correlation Between Nurix Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Nurix Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nurix Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nurix Therapeutics and Molecular Partners AG, you can compare the effects of market volatilities on Nurix Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nurix Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nurix Therapeutics and Molecular Partners.
Diversification Opportunities for Nurix Therapeutics and Molecular Partners
0.47 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Nurix and Molecular is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Nurix Therapeutics and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Nurix Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nurix Therapeutics are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Nurix Therapeutics i.e., Nurix Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between Nurix Therapeutics and Molecular Partners
Given the investment horizon of 90 days Nurix Therapeutics is expected to generate 1.66 times less return on investment than Molecular Partners. But when comparing it to its historical volatility, Nurix Therapeutics is 2.01 times less risky than Molecular Partners. It trades about 0.08 of its potential returns per unit of risk. Molecular Partners AG is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest 407.00 in Molecular Partners AG on August 28, 2024 and sell it today you would earn a total of 155.00 from holding Molecular Partners AG or generate 38.08% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Nurix Therapeutics vs. Molecular Partners AG
Performance |
| Timeline |
| Nurix Therapeutics |
| Molecular Partners |
Nurix Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Nurix Therapeutics and Molecular Partners
The main advantage of trading using opposite Nurix Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nurix Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Nurix Therapeutics vs. Foghorn Therapeutics | Nurix Therapeutics vs. Shattuck Labs | Nurix Therapeutics vs. Monte Rosa Therapeutics | Nurix Therapeutics vs. Kymera Therapeutics |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Complementary Tools
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |